Navigation Links
WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
Date:9/20/2010

WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility -- SHANGHAI, Sept. 20 /PRNewswire-Asia/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Pharmaceuticals, Awards Click to view news release full screen  

WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility

 
Download image

SHANGHAI, Sept. 20 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good Laboratory Practice (GLP) compliance from the Organization for Economic Cooperation and Development (OECD) for toxicology and mutagenicity studies conducted at the company's Suzhou facility.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO)

(Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO)

The OECD is an inter-governmental organization in which representatives of 29 industrialized countries in North America (including the United States), Europe, and the Pacific, as well as the European Commission, work together on issues of mutual concern. The OECD has developed Principles of Good Laboratory Practice to promote the quality and validity of test data used for determining the safety of chemicals and chemical products. Good Laboratory Practice is a quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported.

The certificate recognizes that our Suzhou facility is operating in compliance with OECD Principles of Good Laboratory Practice. Award of the certificate resulted from a one-week inspection conducted by the Belgian national GLP compliance monitoring authority. In addition to an extensive facility assessment, the inspection included an audit of two general toxicology studies and four genetic toxicology studies. The facility inspection evaluated key operational areas, including vivarium rooms, pharmacy, analytical chemistry, clinical pathology, histopathology, and central archive.

"This certificate from the OECD is an important acknowledgment that we now have the capability to offer our clients GLP toxicology studies that meet international GLP quality standards," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "With this award, WuXi moves a step closer to achieving its goal of offering our pharmaceutical and biotech clients a comprehensive, fully integrated platform of pharmaceutical R&D services."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

For more information, please contact: Stephanie Liu (for the media) Tel: +86-21-5046-4362 Email: pr@wuxiapptec.com Ronald Aldridge (for investors) Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... BRIDGEWATER, N.J. , Jan. 16, 2017   Linde ... substantially all of the assets and business of The Service ... respiratory equipment repair services to healthcare providers in the Midwest ... in Broadview, Illinois , The Service Center ... and Greenville, South Carolina . Its primary ...
(Date:1/16/2017)... Jan. 16, 2017  Dovetail Genomics today announced the ... assembly service, which yields chromosome-scale genome assemblies. The service ... Dovetail-hosted workshop on Jan. 17 at the Plant & ... Diego . "We are thrilled to ... of our Dovetail Hi-C offering," said Todd Dickinson ...
(Date:1/16/2017)... Calif. , Jan. 16, 2017  Rigel Pharmaceuticals ... January 3, 2017 and January 16, 2017 the Compensation ... of inducement stock options to purchase an aggregate of ... These awards were granted pursuant to the Rigel Pharmaceuticals, ... to the new employees entering into employment with Rigel, ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon ... , the official journal of The American Society for Aesthetic Plastic Surgery, in ... procedure is designed to correct drooping, retracted lower eyelids, which usually result from ...
(Date:1/16/2017)... Annapolis, Maryland (PRWEB) , ... January 16, 2017 ... ... Kevin Thibodeau has been appointed Chief Executive Officer of the medical device company, ... said Vixiar Chairman Robert Storey. “Kevin has a strong track record in ...
(Date:1/15/2017)... ... , ... Whole Health Supply, LLC is announcing the release of an updated version of their ... , The 2017 edition has wide jaws that will accommodate nails up to 4mm ... as diabetics. This handle is reinforced for extra strength when pressing down on dense nails ...
(Date:1/15/2017)... (PRWEB) , ... January 14, 2017 , ... Wondering where ... Gram Dinner delivered straight to your door for a romantic, lobster feast in the ... in time for Valentine's Day. The dinners will be featured until February 15th, ...
(Date:1/14/2017)... ... 13, 2017 , ... According to a December 9 ... lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern California ... benefits linked to a Mediterranean diet are only some of the many reasons ...
Breaking Medicine News(10 mins):